1. Different Claims Require Different Sources

Official product information is the preferred basis for current product identity, manufacturer, formulation, approved indications, contraindications, warnings, storage and administration information in a specific jurisdiction.

Peer-reviewed clinical research is used for study-specific efficacy and safety outcomes. Reviews and other secondary literature may be used to explain broader concepts or place individual studies in context.

2. How We Read Clinical Trials

When summarizing a clinical study, we aim to identify:

• Study design: randomized, blinded, controlled, multicenter or other relevant features.

• Population and sample size.

• Product, comparator and treatment protocol.

• Primary endpoint and important secondary endpoints.

• Assessment time point.

• Numerical result when it materially improves interpretation.

• Confidence interval, margin or statistical framework when relevant.

• Adverse-event reporting.

• Funding, author employment or conflicts disclosed by the publication.

• Important limitations or reasons not to generalize the result.

3. How We Interpret Non-Inferiority

A non-inferiority trial asks whether a new treatment is not worse than an active comparator by more than a prespecified margin. Meeting a non-inferiority criterion does not automatically prove that two products are identical, universally interchangeable or that the new treatment is superior.

BotoxWiki therefore keeps the endpoint, margin and study population attached to a non-inferiority conclusion.

4. Product Comparisons

A meaningful comparison begins with a defined clinical question. Manufacturer, formulation and approved indications are label or regulatory facts; comparative efficacy and safety require appropriate clinical evidence.

We do not convert unsupported qualitative claims such as “naturalness,” “lifting power,” “diffusion” or “strength” into star ratings or numerical rankings without a transparent, defensible methodology.

5. Botulinum Toxin Units and Dose Comparisons

Botulinum toxin potency units are product-specific and should not be treated as universal mass units. A dose ratio tested in a specific head-to-head trial is reported as part of that protocol; it should not automatically be generalized into a universal cross-brand conversion rule.

6. Safety Evidence

Safety is interpreted in the context of the studied population, indication, dose, injection site, technique and follow-up. An adverse-event rate from one indication should not automatically be transferred to another. Current product labeling remains important for contraindications, warnings and precautions.

7. Funding and Industry-Sponsored Evidence

Industry-sponsored trials are not automatically excluded. Product development frequently involves manufacturer funding. We aim to report the funding source and relevant author conflicts disclosed by the paper and then evaluate the study on its design, conduct, endpoint and reported results.

8. Evidence Strength and Uncertainty

Evidence is not treated as all-or-nothing. A randomized head-to-head trial may answer a narrow comparison question strongly while still leaving uncertainty about other doses, indications, populations or long-term outcomes. Where the evidence does not support a broader claim, BotoxWiki should say so.

9. Updating the Evidence Base

Evidence pages may be updated when important new peer-reviewed research, revised product information or material corrections become available. Updates that change clinical interpretation may require renewed medical review.

• COMPLETE SITE INDEX

Access all clinical evidence methodologies, facial anatomy maps, brand comparison data, and editorial standards currently published across the BotoxWiki platform.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.

All anatomical models, literature reviews, and evidence summaries are strictly peer-reviewed and non-commercial.